Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Aplasia of the ovary, Elevated circulating luteinizing hormone level, Elevated circulating follicle stimulating hormone level, and Delayed puberty and others; and common findings: Delayed menarche and Primary amenorrhea.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lab test results | 2 | Elevated circulating luteinizing hormone level, Elevated circulating follicle stimulating hormone level |
HROB encodes homologous recombination factor with OB-fold (647 aa). DNA-binding protein involved in homologous recombination that acts by recruiting the MCM8-MCM9 helicase complex to sites of DNA damage to promote DNA repair synthesis. Highest expression in Testis (30.2 TPM) and Cells EBV-transformed lymphocytes (15.4 TPM).
Ovarian dysgenesis 11 is associated with mutations in the HROB gene on chromosome 17.
HROB is classified as a druggable target with score 0.0.
Genetic testing for HROB is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for ovarian dysgenesis 11 has been reported in the published literature.
Phenotype severity distribution: 6 always present features, 2 common features.
No clinical trials have been registered for ovarian dysgenesis 11.
50 publications have been identified in PubMed for ovarian dysgenesis 11. Research spans Epidemiology / Natural History (22%), Review / Meta-Analysis (20%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 11 | 22% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 1:07 AM UTC
Online Mendelian Inheritance in Man
Hormones | 2 | Delayed puberty, Primary amenorrhea |
10 |
20% |
Patient case studies | 8 | 16% |
Laboratory research | 8 | 16% |
Testing and diagnosis research | 7 | 14% |
Clinical study results | 6 | 12% |
Liang J (2026). [PMID: 41317609](https://pubmed.ncbi.nlm.nih.gov/41317609/). *European journal of obstetrics, gynecology, and reproductive biology*. [Review / Meta-Analysis]
Dong Y (2026). [PMID: 41555764](https://pubmed.ncbi.nlm.nih.gov/41555764/). *Am J Med Genet A*. [Review / Meta-Analysis]
Karatas E (2026). [PMID: 41569008](https://pubmed.ncbi.nlm.nih.gov/41569008/). *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. [Diagnostic / Biomarker]
Bahmad HF (2026). [PMID: 42168620](https://pubmed.ncbi.nlm.nih.gov/42168620/). *Virchows Arch*. [Diagnostic / Biomarker]
Shuai X (2026). [PMID: 42165018](https://pubmed.ncbi.nlm.nih.gov/42165018/). *Front Endocrinol (Lausanne)*. [Case Report / Case Series]
Zhang Q (2026). [PMID: 41918383](https://pubmed.ncbi.nlm.nih.gov/41918383/). *Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics*. [Case Report / Case Series]
Fabbri-Scallet H (2026). [PMID: 41688582](https://pubmed.ncbi.nlm.nih.gov/41688582/). *Scientific reports*. [Clinical Trial Publication]
Simard C (2025). [PMID: 40921077](https://pubmed.ncbi.nlm.nih.gov/40921077/). *Annals of internal medicine*. [Diagnostic / Biomarker]
Virtanen N (2025). [PMID: 39800132](https://pubmed.ncbi.nlm.nih.gov/39800132/). *Fertility and sterility*. [Epidemiology / Natural History]
Sang YQ (2025). [PMID: 41337645](https://pubmed.ncbi.nlm.nih.gov/41337645/). *Neuro endocrinology letters*. [Review / Meta-Analysis]